SOPHiA GENETICS is excited to celebrate Clinical Trials Day. This blog dives a little deeper into the history of clinical trials and how they continue to advance healthcare.
Diversity in Genomic Analysis: An example of how SOPHiA GENETICS has built more accurate health data analysis for diverse populations
Every person is unique. We can clearly see this within the more than one million genomic profiles from 70 different countries analyzed by our technology.
Third party sequencing services can enable increased access to NGS testing, but if institutions do not receive access to the raw data it can limit the insights they can gain. Doing the data analysis in house can allow you to harness the power of genomic data to reveal relevant variants.
SOPHiA GENETICS has reached a major milestone on a global scale by analyzing one million genomic profiles.
The field of precision medicine continues to evolve but remains steadfast in its goal to provide the right treatment to the right patients at the right time. This blog examines the evolution of precision medicine and how we can achieve its promise.
How Protean BioDiagnostics utilizes SOPHiA GENETICS for more comprehensive genomic analysis and research
Larger panels may cast wider nets, but optimization with patented algorithms through our universal platform gives more actionable insights without sacrificing data quality.
Increased access to genomic testing can help fulfill the promise of making precision medicine accessible to all, but the upfront investment required for institutions to start their own sequencing labs remains a barrier. This challenge can be overcome by using sequencing service.
By leveraging expertly curated evidence, powered by JAX-CKB, and SOPHiA GENETICS’ patented algorithms through the SOPHiA DDM platform, users can then use OncoPortal™ Plus to accurately identify clinical associations and actionable biomarker profiles.
The President acknowledged that the US still has much further to come in advancing data-driven initiatives and that many Americans sadly do not realize the struggle of seeking answers during the cancer diagnostic journey until it’s too late.
2021 has been a big year for SOPHiA GENETICS. Here’s a recap of some of the major highlights…
Radiomics maximizes upon information that’s already being collected. The difference is how that info is used.
About half of all breast cancer patients develop the disease outside of the period of ages 50-69 and could greatly benefit from earlier detection. Today, we know that age alone is not enough to accurately estimate breast cancer risk.